Treatment references

Part 2

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. New Engl J Med. 2014;371:326–38.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate to severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015b; 172:1371–83.

Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011;64:936–49.

Lebwohl M, Sherif B, Mollon P, Willimas N, Fox T, Papavassilis C, et al. Secukinumab relieves pain and anxiety in psoriasis: Results of two Phase 3 trials. EADV. Copenhagen, Denmark. 7–11 October 2015a. P1704.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015b;373:1318–28.

Lebwohl M, Iversen L, Eidsmo L, Messina I, You R, Milutinovic M. Long-term psoriasis control following secukinumab discontinuation indicated disease modification of moderate to severe psoriasis. 13th Annual Maui Derm for Dermatologists 2017. 20–24 March 2017.

Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018a;79(2):266–76.e5.

Lebwohl M, Ghislain P-D, Kerdel F, Gu Y, Valdes JM, Thompson EHZ, et al. Efficacy of risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018b. OP01.04.

Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018c;78(1):81–89.

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22.

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 76-week results from a randomised, double-blind placebo-controlled trial (PHOENIX-1). Lancet. 2008;371:1665–74.

Leonardi CL. Data on the safety of psoriasis therapies. Sem Cutaneous Med Surg. 2014;33:S73–5.

Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824–830.

Leonardi C, Gara A, Amato D, Osenenko K, Setayeshgar S, Wang S, et al. Disease severity and quality of life among ixekizumab-treated psoriasis patients in the real-world setting: Results from a single US dermatology referral practice. 2019 AAD Annual Meeting. Washington D.C. March 1–5, 2019. Poster 8211.

Lilly, 2019 [press release]. Lilly announces superiority of taltz® (ixekizumab) versus tremfya® (guselkumab) in delivering total skin clearance at week 12 in topline results from head-to-head (IXORA-R) trial in people living with moderate to severe plaque psoriasis. Available at https://www.prnewswire.com/news-releases/lilly-announces-superiority-of-taltz-ixekizumab-versus-tremfya-guselkumab-in-delivering-total-skin-clearance-at-week-12-in-topline-results-from-head-to-head-ixora-r-trial-in-people-living-with-moderate-to-severe-plaque-pso-300900135.html (accessed September 2019).

Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068.

Litjens NHR, Rademaker M, Ravensbergen B, Rea D, van der Plas MJA, Thio B, et al.  Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004;34:565–75.

Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014 Sep 15;7:251–9.

Luger T, Schopf RE, Schwanke A, Langhammer S, Meng T, Löschmann PA. An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2016;30:1730–41.

Mahlich J, Alba A, Hadad LE, Leisten MK, Peitsch WK. Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: A retrospective claims database analysis. Adv Ther. 2019;36(7):1684–1699.

Matoula T, Kostopoulos N, Kyriazis N, Panagakis P. Psoriasis. Long-term efficacy and safety of infliximab maintenance therapy after 104 weeks of treatment in 50 patients with plaque-type psoriasis. EADV. Copenhagen, Denmark. 7–11 October, 2015. P1663.

Mease P, Armstrong A. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs 2014;74:423–41.

Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2007;31:e1–15.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.

Menter A, Thaçi D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, et al.  Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73:410–9.

Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016a;30:1148–58.

Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016b;6:639–647.

Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, et al. Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials.J Drugs Dermatol. 2016c;15:568–80.

Menter A, Sobell J, Silverberg JI, Lebwohl M, Rastogi S, Pillai R, et al. Long-term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial. Winter Clinical Dermatology Conference. Lahaina Hawaii. January 12-17, 2018. Poster 147. Available at https://jofskin.org/index.php/skin/article/view/253/257 (accessed March 2019)

Methofill, Summary of Product Characteristics. 2018. Available at https://www.medicines.org.uk/emc/product/9057/smpc (accessed September 2019).

Methotrexate, Summary of Product Characteristics. 2015. Available at https://www.medicines.org.uk/emc/product/6790 (accessed September 2019).

Mirikizumab, ClinicalTrials.gov. Available from:  https://clinicaltrials.gov/ct2/results?cond=&term=mirikizumab&cntry=&state=&city=&dist=y (accessed September 2019).

Morita A Current developments in phototherapy for psoriasis. J Dermatol. 2018;45:287–292.

Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36.

Mrowietz U, Szepietowski JC, Loewe R, Van de Kerkhof P, Lamarca R, Ocker WG, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: A randomised, double-blind, Fumaderm® and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176:615–23.

Mrowietz U, Barker J, Boehncke W-H, Iversen L, Kirby B, Naldi L, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32:3–14.

Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol. 2005;152:597–615.

Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10 Suppl 2:S1–95.

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94.

NCT03384745, ClinicalTrials.gov. A phase 2b study of the efficacy, safety, and tolerability of M1095 in subjects with moderate to severe psoriasis. Available at https://clinicaltrials.gov/ct2/show/NCT03384745 (accessed September 2019).

NCT03390101, ClinicalTrials.gov. An international multicenter, randomized, double-blind, placebo-controlled clinical study of efficacy and safety of two dosing regimens of BCD-085 (JSC BIOCAD, Russia) in patients with moderate to severe plaque psoriasis (BCD-085-7). Available at https://clinicaltrials.gov/ct2/show/NCT03390101 (accessed September 2019).

NCT03553823, Clinicaltrials.gov. Comparison of secukinumab versus guselkumab in clearing psoriatic plaques refractory to ustekinumab (ARROW). Available at https://clinicaltrials.gov/ct2/show/NCT03553823 (accessed September 2019).

Neoral, Summary of Product Characteristics. 2016. Available at https://www.medicines.org.uk/emc/product/1034/smpc (accesdsed September 2019).

Nguyen C, Beroukhim K, Danesh M, Leon A, Sorenson E, Huynh M, et al. A single-center, open-label study assessing the change in psychosocial and occupational well-being before and after treatment with ustekinumab in patients with moderate-to-severe psoriasis. 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015. Abstract 2983379.

Nograles KE, Davidovici B, Kreuger KG. New insights into the immunological basis of psoriasis. Semin Cutan Med Surg. 2010;29:3–9.

Olumiant, Prescribing Information, 2018. Available at   https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf (accessed September 2019).

Olumiant, Summary of Product Characteristics, 2018. Available at  https://www.medicines.org.uk/emc/product/2434/smpc (accessed September 2019).

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reductions. Br J Dermatol. 2005;152:1304–12.

Papp KA, Langle RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 52 week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84.

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015a;73:37–49.

Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al.Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015b;14:706–14.

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, et al. OPT Pivotal 1 and OPT Pivotal 2 Investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials. Br J Dermatol. 2015c;173:949–61.

Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. Am J Clin Dermatol. 2016a;17(1):79–86.

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016b;175:273–86.

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaçi D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016c;74(5):841–50.

Papp K, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A Randomized Phase 2b Trial of Baricitinib, an Oral JAK1/JAK2 Inhibitor, in Patients with Moderate-to-Severe Psoriasis. Br J Dermatol. 2016d;174:1266–76.

Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40–49.

Papp K, Reich K, Blauvelt A, Thaçi D, Sinclair R, Tyring SK, et al. Clinical efficacy of tildrakizumab with chronic plaque psoriasis over 2 years of treatment: Result from long-term extension to 2 phase 3 clinical studies. Presented at the 13th Winter Clinical Dermatology Conference. January 12‒17, 2018a. Maui, HI, USA.

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018b;79(2):277–286.

Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018c;379:1313–21.

Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. Br J Dermatol. 2019;180(6):1352–1360.

Pariser D, Wu JJ, Strober B, Bagel J, Song M, Shen Y-K, et al. Drug survival is superior among patients treated with guselkumab compared to adalimumab in the VOYAGE 1 trial. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1937.

Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A. et al. European S3 guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venerol. 2009;23(suppl 2):5–70.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015a;173:1387–99.

Paul C, Lacour J-P, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015b;29:1082–90.

Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70–79.

PubChem, 2019. Halobetasol propionate. Available at https://pubchem.ncbi.nlm.nih.gov/compound/Halobetasol-propionate (accessed September 2019).

Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, et al. Biosimilars in Dermatology: Current Situation (Part I). Actas Dermosifiliogr. 2015;106:545–9.

Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: An integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol. 2019 Jun 26. [Epub ahead of print].

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: A phase III multicentre, double-blind trial. Lancet. 2005;366:1367–74.

Reich K, Sullivan J, Arenberger P, Morwietz U, Regnault, P, Chen P, et al. Secukinumab is effective in subjects with nail psoriasis: 16 week results from the transfigure study. 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015. Abstract 3086561.

Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2016a;31:507–17.

Reich K, Papp K, Blauvelt A, Tyring SK, Sinclair R, Thaci D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised, controlled, phase 3 trials. Lancet. 2017a;390(10091):276–288.

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017b;76:418–31.

Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017c;176(3):752–758.

Reich K, Griffiths CEM, Iversen L, Peserico A, Pau-Charles I, Blauvelt A, et al. Improvements in dermatology-specific health-related quality of life in patients with moderate-to-severe psoriasis treated with tildrakizumab: pooled results from reSURFACE 1 and reSURFACE 2 phase 3 trials. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018a. P1919.

Reich K, Maari C, Heredia EE, Zhu B, Kletoka P, Li J, et al. Mirikizumab improves patient-reported signs and symptoms of psoriasis. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018b. P1823.

Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019a;394(10201):831–839.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019b;180(5):1039–1049.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG et al. Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent trial. 2019 AAD Annual Meeting, Washington DC, 01–05 March 2019c. 10218. Available at: https://www.aad.org/eposters/Submissions/getFile.aspx?id=10218&type=sub (accessed March 2019). 

Remicade, Summary of Product Characteristics, 2015. Available at http://www.medicines.org.uk/emc/medicine/3236 (accessed September 2019).

Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134–42.

Rompoti N, Katsimbri P, Kokkalis G, Boumpas D, Ikonomidis I et al. Theodoropoulos K,et al. Real world data from the use of secukinumab in the treatment of moderate‐to‐severe psoriasis, including scalp and palmoplantar psoriasis: A 104‐week clinical study. Dermatol Ther. 2019;32(5):e13006.

Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015;15:877–84.

Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA. 2011;306:864–71.

Samtsov AV, Khairutdinov VR, Bakulev AL, Kubanov AA, Karamova AE, Artem’eva AV, et al. Efficacy and safety of BCD-085, a novel interleukin-17 inhibitor. Results of phase II clinical trial in patients with moderate-to-severe plaque psoriasis. Vestnik Dermatologii i Venerologii 2017:52–63.

Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47-62.

Saurat JH, Dubertret SG, Papp K. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–66.

Schreiber S, Sands BE, Deodhar A, Baeten D, Huang J, Gandhi K, et al. No increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies. Ann Rheum Dis 2016;75(Suppl2):97.

Shear NH, Hartmann M, Toledo-Bahena ME3 Gilbert M, Katsambas A, Yao R, Popmihajlov Z. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice. Qual Life Res. 2016;25:2031–40.

Shelton SK, Bai SR, Jordan JK, Sheehan AH. Ixekizumab: A review of its use for the management of moderate to severe plaque psoriasis. Ann Pharmacother. 2019;53(3):276–284.

Skyrizi, Summary of Product Characteristics, 2019. Available at https://www.medicines.org.uk/emc/product/10199 (accessed September 2019).

Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013;191(5):2205–16.

Steeland S, Vandenbroucke RE, Libert C: Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today 2016, 21:1076–1113.

Stein GL, Bagel J, Lebwohl MG, Lin T, Martin G, Pillai R. Halobetasol and tazarotene: further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2018;17:1290–6.

Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, et al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17(2):221–8.

Stelara, Summary of Product Characteristics, 2015. Available at  https://www.medicines.org.uk/emc/product/4412/smpc (accessed September 2019).

Strober B, Mordin M, Mollons P, Williams N, Fox T, Papavassilis, et al. Secukinumab demonstrates greater impact on patient global impression of change than etancercept in moderate to severe psoriasis. EADV. Copenhagen, Denmark. 7–11 October 2015. P1702.

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016a;55:401–7.

Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016b;74:851–861.e4.

Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: Week 16 results from the UNVEIL study. J Drugs Dermatol. 2017a;16(8):801–808.

Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017b;76:655–61.

Strober B, Lambert J, Gu Y, Thompson EHZ, Valdecantos W, Menter A. Impact of prior treatment history on efficacy of risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1867.

Summary of Product Characteristics, Otezla, 2015 [cited 5 December 2015]. Available from: https://www.medicines.org.uk/emc/print-document?documentId=29792.

Sun Pharma press release. Sun Pharma announces receipt of European Commission approval for ILUMETRI®(tildrakizumab) by Almirall for treatment of moderate-to-severe chronic plaque psoriasis.Available at http://www.sunpharma.com/Media/Press-Releases/Press%20Release%20European%20Commission%20Approval%20For%20ILUMETRI.pdf (accessed September 2019).

Taltz Summary of Product Characteristics, 2016. Available at https://www.medicines.org.uk/emc/product/7233/smpc (accessed September 2019).

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomised controlled trial. J Am Acad Dermatol 2015;73:400–9.

Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31:498–506.

Thaci D, Termeer C, Sebastian M, Pinter A, Sticherling M, Gerdes S, et al. Guselkumab is superior to fumaric acid esters in patients with moderate to severe plaque psoriasis who are naive to systemic treatment: Initial results from the Phase 3b POLARIS trial. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018a. OP01.05.

Thaci D, Griffiths CEM, Iversen L, Peserico A, Kimball AB, Pau-Charles I et al.Long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis who were non-responders or partial responders to etanercept in the phase 3 reSURFACE2 trial. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018b. P1923.

Thaçi D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. J Am Acad Dermatol. 2019: S0190-9622(19)30640-1 [Epub ahead of print].

Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010; 184:5298–307.

Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019;47(6):2342–2350.

Tremfya, Prescribing Information, 2017. Available at https://www.janssenmd.com/pdf/tremfya/tremfya_pi.pdf (accessed September 2019).

Tremfya, Summary of Product Characteristics, 2017. Available at https://www.medicines.org.uk/emc/product/8662 (accessed September 2019).

U.S. Food and Drug Administration [FDA News Release]. FDA approves new psoriasis drug Cosentyx. January 2015. Available at http://wayback.archive-it.org/7993/20180126023512/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm (accessed September 2019).

U.S. Food and Drug Administration [FDA News Release]. FDA approves new psoriasis drug Taltz. January 2015. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm (accessed September 2019).

U.S. Food and Drug Administration [FDA News Release]. FDA approves new psoriasis drug. February 2017. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm541981.htm (accessed September 2019).

Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016;30:1753–9.

van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, et al.  Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29:2002–10.

Vilarrasa E, Notario J, Bordas X, López-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74:1066–72.

Warren RB, Finlay AY, Barker J, Burden A, Armendariz Y, Williams R, et al. The efficacy and safety of secukinumab in psoriasis patients classed as non-responders to anti-TNF alpha therapy; 72 week data from the SIGNATURE study. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1981.

Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg. 2013;17:6–12.

Xeljanz, Prescribing Information, 2018. Available at  https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf. (accessed September 2019).

Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: A literature review of IL-17 inhibition. J Drugs Dermatol. 2015;14:244–50.

Yan K, Zhang Y, Han L, Huang Q, Zhang Z, Fang X, et al. Safety and efficacy of methotrexate for Chinese adults with psoriasis and without psoriatic arthritis. JAMA. 2019;155(3):327–334.

Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers in Medical Science 2018;33:173–180.

Zweegers J, Groenewoud JM, van den Reek JM, Otero ME, van de Kerkhof PC, Driessen RJ, et al. Comparison of the one and 5-years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: Results from the prospective BioCAPTURE registry. Br J Dermatol. 2017;176:1001–9.

In the next section discover the Guidelines and Resources available
Login/ Register Maximise Minimise